1. Home
  2. GVA vs CRSP Comparison

GVA vs CRSP Comparison

Compare GVA & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GVA
  • CRSP
  • Stock Information
  • Founded
  • GVA 1922
  • CRSP 2013
  • Country
  • GVA United States
  • CRSP Switzerland
  • Employees
  • GVA N/A
  • CRSP N/A
  • Industry
  • GVA Military/Government/Technical
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GVA Industrials
  • CRSP Health Care
  • Exchange
  • GVA Nasdaq
  • CRSP Nasdaq
  • Market Cap
  • GVA 4.2B
  • CRSP 3.4B
  • IPO Year
  • GVA 1990
  • CRSP 2016
  • Fundamental
  • Price
  • GVA $94.75
  • CRSP $41.51
  • Analyst Decision
  • GVA Hold
  • CRSP Buy
  • Analyst Count
  • GVA 2
  • CRSP 19
  • Target Price
  • GVA $67.00
  • CRSP $77.13
  • AVG Volume (30 Days)
  • GVA 504.8K
  • CRSP 1.7M
  • Earning Date
  • GVA 02-20-2025
  • CRSP 02-19-2025
  • Dividend Yield
  • GVA 0.55%
  • CRSP N/A
  • EPS Growth
  • GVA 144.49
  • CRSP N/A
  • EPS
  • GVA 2.18
  • CRSP N/A
  • Revenue
  • GVA $3,963,969,000.00
  • CRSP $202,829,000.00
  • Revenue This Year
  • GVA $14.59
  • CRSP N/A
  • Revenue Next Year
  • GVA $6.86
  • CRSP $724.16
  • P/E Ratio
  • GVA $43.57
  • CRSP N/A
  • Revenue Growth
  • GVA 17.81
  • CRSP 19.31
  • 52 Week Low
  • GVA $43.92
  • CRSP $36.52
  • 52 Week High
  • GVA $105.20
  • CRSP $91.10
  • Technical
  • Relative Strength Index (RSI)
  • GVA 63.02
  • CRSP 47.98
  • Support Level
  • GVA $85.56
  • CRSP $36.52
  • Resistance Level
  • GVA $90.99
  • CRSP $40.99
  • Average True Range (ATR)
  • GVA 2.21
  • CRSP 1.79
  • MACD
  • GVA 0.74
  • CRSP 0.35
  • Stochastic Oscillator
  • GVA 92.18
  • CRSP 64.30

About GVA Granite Construction Incorporated

Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. It focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, with the remainder derived from its Materials segment.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: